Bluejay Compresses Share Count with 1-for-4 Reverse Split (BJDX)

Bluejay Diagnostics, Inc. (BJDX) compressed its public float and tightened the capital structure by converting every four shares into one, a move management says was designed to simplify the equity picture.

BJDX stock chart

BJDX

In a new disclosure, the company said the board selected and implemented a 1-for-4 reverse stock split that became effective on Jan. 29, 2026.

What changed on the surface — and why it matters

The math is straightforward: issued and outstanding common shares fell from about 2,834,133 to approximately 708,533 after the 1-for-4 split. That reduction is more than cosmetic. Compressing the share count can make per-share metrics look healthier, reduce the number of outstanding shares that can be bought up by a small group, and sometimes help meet exchange standards or investor expectations about minimum share price and float.

The split also touched the company’s derivative instruments. The number of shares issuable upon prefunded warrants was reduced proportionately, from 1,055,000 to 263,750. Outstanding stock options, restricted stock units and other equity awards were adjusted on the same 1-for-4 basis, and the reserve under the company’s equity plans was trimmed accordingly. Those proportional changes keep the economic position of optionholders and warrant holders intact in percentage terms, but they do change the shape of the cap table and the raw share counts investors watch.

How trading and fractions were handled

Trading resumed on The Nasdaq Capital Market on a post-split basis using the same ticker, BJDX, and the company reported a new CUSIP of 095633608. No fractional shares were issued — holders who would otherwise have been due a fractional share will receive cash in lieu through the exchange agent’s process.

For traders, the split is already reflected in the market: a recent trading snapshot shows the stock closed at $3.62 on Jan. 30, 2026 and was trading above its 20-day moving average; its 14-day RSI sits in the overbought neighborhood. Those technicals tell a story of short-term momentum, but remember the split itself reshapes per-share numbers and can briefly amplify percentage moves.

Where Bluejay sits as a business

Bluejay is a small medical-technology company building rapid, near-patient diagnostics on its Symphony platform, with an IL-6 sepsis triage test that aims to deliver results in roughly 20 minutes. The company does not yet have U.S. regulatory authorization to market Symphony, and it has been operating with limited revenue while it advances product development and seeks regulatory clearance — context that helps explain why management wanted a leaner share base. For more background on the business and its risks, see what the company does.

Why investors should care beyond the headline

A reverse split is not a capital infusion and it doesn’t improve cash on hand, but it does change optics and mechanics in ways investors should track. First, with outstanding shares reduced to roughly 708,533, each remaining share represents a larger slice of ownership — that can tighten apparent float and increase per-share earnings or loss metrics when calculated on a post-split basis.

Second, the proportional cut to prefunded warrants and equity awards matters because warrant dilution — when exercisable — is a key overhang for microcap issuers like Bluejay. Reducing the nominal number of shares attached to those instruments doesn’t change the underlying value of the agreements, but it does reduce the headline number of shares that could hit the market if holders exercise.

Third, the split may have been partly practical: the company’s stock had previously traded at very low levels, and the board had shareholder authorization on June 18, 2025 to compress the share base at ratios between 1-for-2 and 1-for-20. The board chose the conservative 1-for-4 option, which suggests a desire to improve trading characteristics without an extreme consolidation.

Concrete items for investors to watch next

• Cash runway and quarterly results — with a reported cash balance of about $3.08 million as of Sept. 30, 2025, investors should watch the company’s next financial update to see how the balance has moved and whether additional financing is needed.
• Regulatory progress for Symphony — because commercial revenue depends on authorization, any milestone or announcement about clinical data or regulatory review will be a material trigger for valuation.
• Warrant and option exercises — watch for notices or filings that signal large exercises or conversions; while counts were cut proportionately, the economic outcomes remain important for dilution and treasury inflows.
• Trading behavior after the split — splits can temporarily boost liquidity or volatility; if momentum stalls or selling pressure returns, the stock could revisit pre-split levels in percentage terms.

Investors should treat the split as a housekeeping move to tidy the capital structure rather than as an operational fix. The company’s strategic story — getting Symphony to market and extending cash runway until meaningful revenue or a financing arrives — still drives the long-term thesis. For the precise language behind the change, see the new disclosure, and for the company press materials see the supporting materials.